The proverbial ‘pill’ or hormonal contraception may be available over-the-counter (or at least a progestin-only version) by year’s end. Join guest host, Jake Galdo, as he discusses improved access to care with Erin Raney as the FDA debates over-the-counter status for hormonal contraceptives.

The GameChanger
Women’s health is a priority area from a public health perspective – the US has lots of room for improvement. One initiative is to allow a progestin-only hormonal contraceptive have over-the-counter status; in other words, be available without a prescription. Progestin-only therapy has unique counseling considerations, so pharmacy intervention can help to optimize care. 

Host
Jake Galdo, PharmD, MBA, BCPS, BCGP
Course Content and Developer, CEimpact
Managing Network Facilitator, CPESN Health Equity
CEO, Seguridad

Guest
Erin C. Raney, Pharm.D., BCPS, BC-ADM
Professor of Pharmacy Practice
Midwestern University College of Pharmacy-Glendale

References and Resources
Opill Rx-to-OTC Switch Program. www.fda.gov/media/167893/download

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)

CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the efficacy of OTC hormonal contraceptive
2. Identify contraindications for OTC hormonal contraceptives

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-211-H01-P
Initial release date: 5/29/2023
Expiration date: 5/29/2024

Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram